2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: ...

Biotech company Amgen (NASDAQ:AMGN) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 12.4% year on year to $9.56 billion. The company’s full-year revenue guidance of $36.2 billion ...

Well...that's the premise of Zomato co-founder and ex-Shark Deepinder Goyal's brand-new venture, Continue Research. He ...

Sensei Biotherapeutics is abandoning its sole clinical-stage drug and warning of imminent layoffs as the company mulls its ...

A global conference showcasing AI-led scientific research revealed both the growing role of AI in academia and its persistent ...

The group says its vaccine business will recover in the medium term when falling immunisation rates cause a severe public ...

Once this policy is enacted, it will be illegal for Americans to retain any mental impression longer than that little haptic ...

Biopharma has finally begun catching up with the overall stock market, as shares of the top three biopharma exchange traded funds (ETFs) jumped well into double digits over the past six months.

E. John Wherry, director of Penn's Colton Center for Autoimmunity, spoke with the Inquirer about the future of immunology ...

Discover the surprising power of peas! These humble legumes are nutritional powerhouses, packed with protein, fibre, vitamins ...

Sarepta Therapeutics, Inc. faces revenue decline, trial setbacks, and FDA decisions. Click for SRPT risks, outlook, and if ...